Objective. To identify predictors of ICU mortality in patients with hemoblastosis and infectious complications. Material and methods. The study included 202 ICU patients with hemoblastosis and infectious complications between 2018 and 2021. We evaluated SIRS, qSOFA and SOFA scores, as well as other potential significant predictors. Binomial multiple logistic regression approach was used to create prognostic model. Results. Mortality rate was 33% (67 out of 202), odds ratio — 0.49 (67 to 136). The median of the follow-up period was 6 (3-14) days. Univariate analysis revealed tachypnea, hypoxemia, hemodynamic instability (blood pressure decrease, need for vasopressor support), liver damage (hyperbilirubinemia, hypoproteinemia, hypoalbuminemia) and impaired consciousness as predictors of ICU mortality. Multivariate analysis revealed 3 significant predictors of mortality: impaired consciousness, platelet count and serum protein. Model quality was evaluated on a test set with a threshold of high probability of death ≥32%. Accuracy was 0.816 (95% CI 0.679-0.912), sensitivity — 0.80, specificity — 0.82. Conclusion. Impaired consciousness, decreased platelet count and serum protein are the most important predictors of mortality in ICU patients with hemoblastosis and infectious complications. These data can be used in clinical practice.
2 August 2022 in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
The ICU department’s mortality rate is one of the most important indicators of quality of care. Based on real clinical data, we attempted to build a prognostic model for patients with blood diseases in the ICU with using of the logistic regression method. The study included 202 patients in total. The median age was 57 (19–82) years. There were 112 (55 %) males and 90 (45 %) females. The statistical analysis was performed by using R software, version 3.4.2. The absolute risk of death (mortality rate) was 67 from 202 (33 %), odds — 0.496. The odds of death in ICU grow up to ~20 times if the patient has a Glasgow score of less than 15. Also, the odds of death increase by 1.3 and 11 times of PLT, or serum total protein level decreases by 2 times accordingly. Our model for “high-risk of death” detection classified patients in the test dataset with 0.816 accuracy (95 % CI 0.679–0.912), with sensitivity 0.823, and specificity 0.80. Despite the simple method for data analysis, we got a pretty accurate model of mortality prognosis with efficacy more than qSOFA and MEWS scales. Research in this area should continue.
Background. Patients with lymphoproliferative disorders (LPD) are at increased risk of developing venous thromboembolic complications (VTEC). Existing risk assessment systems for VTEC (Khorana, Vienna, ThroLy, etc.) do not have sufficient prognostic accuracy in this patient population. The thrombodynamics test may improve the prognosis of VTEC and optimize the prophylactic use of anticoagulants in these patients.Aim. To evaluate thrombodynamics test efficacy in assessing the risk of venous VTEC in LPD patients.Materials and methods. Medical data of 990 patients with LPD who received treatment at the Kirov Research Institute of Hematology and Blood Transfusion from 2019 to 2021 were analyzed. Coagulation parameters were evaluated at admission, as well as the risk of developing VTEC by prognostic scales Khorana, Vienna, ThroLy, SAVED, and Padua. Data are presented as median and interquartile range. Mann–Whitney U test was used to compare two independent groups. Correlation was determined using Spearman’s rank correlation. Logistic regression was used to determine dependencies. The diagnostic value of laboratory tests was established through ROC analysis.Results. In the overall cohort of LPD patients, the incidence of VTEC was 2.1 %. Screening coagulogram parameters in these patients did not exceed reference values. Patients with LPD who developed VTEC initially showed a significant increase in clot velocity (V), initial growth velocity (Vi), and clot size (Cs). It was found that the presence of spontaneous clots significantly increased the chances of developing a thrombotic event (odds ratio 3.99; 95 % confidence interval 1.56–10.22; p = 0.004). It was also determined that V velocity is an independent predictor of VTEC (adjusted odds ratio 1.053; 95 % confidence interval 1.016–1.090; p = 0.0046). The AUC determined by ROC analysis for the V parameter was 0.722 (threshold value 30.7 μm/min sensitivity 81 %, specificity 57.4 %).Conclusion. Clot growth velocity is the most informative parameter of thrombodynamics test in predicting VTEC.
4 July 2020 in Russian Journal of Pediatric Hematology and Oncology
Relevance.Reliable and long-term venous access is one of the most important condition for a successful leukemia therapy in children. Safe and convenient access to a central vein allows to provide chemotherapy, adjuvant treatment, parenteral nutrition and blood transfusion. It decreases the likelihood of phlebitis development and reduction of the peripheral venous network in comparison with peripheral venous access. The use of totally implantable venous port systems reduces risks of severe complications associated with re-catheterization of the central vein thus it improves patient’s quality of life.The purpose of the studyis a retrospective assessment of the experience of use and analysis of the complications of totally implantable venous port systems in children with diseases of the blood system.Materials and methods.The data of 61 patients of the pediatric hematology clinic with venous port systems have been analyzed.Results.Perioperative complications developed in 3 (4.9 %) patients Median time of using of port systems was 679 catheter-days. Delayed complications requiring removal of the device developed in 8 (13.1 %) patients. Infectious complications were the reason for device removal in 3 (2.9 %) patients, mechanical complications in 5 (8.2 %) patients. No thrombotic complications were found.Conclusions.The use of venous port systems in children with hematologic diseases for a long period of time is an effective and safe way for central venous access providing.
22 October 2022 in Russian journal of hematology and transfusiology
Introduction. Sepsis is one of the main causes of high mortality in oncohematological patients. Sepsis is diagnosed using different scoring scales, but the accuracy of the diagnosis varies.Aim — to determine the effectiveness of SIRS, qSOFA and MEWS scales for the diagnosis of sepsis in oncohematological patients.Materials and methods. Study participants included 202 patients hospitalized in the intensive care unit with infectious complications — 112 (55 %) male, 90 (45 %) female. The median age was 57 years. The estimated predictors were the criteria of SIRS, qSOFA and MEWS scales and other significant indicators. The Boruta method was employed to select the predictors. A multiple binomial logistic regression model was used to determine the prognostic value of the predictors. The probability of sepsis was calculated based on the regression equation. The correlation between sepsis probability and the prognostic scales was assessed using correlation analysis (Kendall rank correlation coefficient).Results. Diagnoses were confirmed by scales in 95 of 202 (47 %) patients: SIRS — in 77 (81 %), qSOFA — in 31 (33 %), MEWS — in 65 (68 %). Of the 19 predictors initially included in the study, the final logistic regression model included 6: respiratory rate, heart rate, impaired urine output, systolic blood pressure, body temperature, and Glasgow coma scale level, which matched MEWS criteria. The median probability of sepsis was 0.38 (0.079–0.921). The results of the calculated probability of sepsis, according to the logistic regression model, correlated most closely with the score on the MEWS scale, to a lesser extent — with that on SIRS and qSOFA.Conclusion. The MEWS scale is a more suitable tool for the diagnosis of sepsis than SIRS and sofa in oncohematological patients.
The incidence of malignant lymphomas has been increasing in recent years worldwide. These diseases are often accompanied by venous thromboembolic complications (VTEC). The development of VTEC leads to interrupting of therapy, increasing mortality and significant rising of treatment costs. Anticoagulants are effective in VTEC prophylaxis. Prescribing of anticoagulant therapy is based on VTEC different risk scales, which are far from perfect. The search of additional features for hemostasis assessment can increase the prognostic value of these scales. The optimization of VTEC risk scales can improve efficacy of anticoagulant therapy and decrease an incidence of thrombotic events in patient with malignant lymphomas. The article presents a literature review and own clinical observations regarding the VTEC risk assessment in patients with lymphoproliferative diseases.